Merit Medical Systems (MMSI) reported strong Q2 earnings, exceeding market expectations for both EPS and sales. The company subsequently raised its full-year 2026 adjusted EPS and sales guidance, leading analysts to increase their price targets for the stock.
Merit Medical Systems (MMSI) delivered a significant positive surprise in its Q2 earnings, beating analyst estimates on both the top and bottom lines. This strong performance, driven by 9% organic revenue growth and improved operating margins, prompted the company to raise its financial guidance for FY2026. This is a major catalyst as it indicates robust operational health and future growth prospects. The immediate impact was a 4.4% gain in pre-market trading, and analysts from BTIG and Needham subsequently raised their price targets, signaling continued positive sentiment. For traders, this presents an opportunity for further upside, though potential risks include broader market downturns or unforeseen operational challenges.